Home & News

Support & Concepts for Innovative Cancer Drug Development           

Create New Horizons

Welcome to Hentsch Consulting

Our goal is to support your innovative cancer drug developments and to translate those into new cancer drug concepts

News

May 2020

Scientific update 2018 - 2020

During the past 2 years I supported the development of INTH-454, a novel small molecule acting via a new mode-of-action to cause death of cancer cells. Data were presented as posters/oral presentation on the following oncology conferences:

ASCO 2019, AACR 2019, AACR-EORTC 2019 and ASCO 2018.

2019

Valentino Cattori, Bernd Hentsch, Ulrich Kessler (2019): DOI:10.1200/JCO.2019.37.15_suppl.3105 Journal of Clinical Oncology 37, no. 15_suppl (May 20, 2019) 3105-3105 (Poster ASCO 2019)

Valentino Cattori, Bernd Hentsch and Ulrich Kessler (2019):

Mol Cancer Ther 2019;18(12 Suppl): Abstract nr C040. doi:10.1158/1535-7163.TARG-19-C040 (Poster AACR EORTC 2019)

Hentsch B, Cattori V, Labelle M, Kessler U.

Proceedings of the American Association for Cancer Research Annual Meeting 2019; 2019 Mar 29-Apr 3; Atlanta, GA. Philadelphia (PA): AACR; Cancer Res 2019;79(13 Suppl):Abstract nr 2694 (Oral presentation AACR 2019).

2018

Ulrich Kessler, Valentino Cattori, Marc Labelle, Bernd Hentsch (2018):

DOI: 10.1200/JCO.2018.36.15_suppl.e14581 Journal of Clinical Oncology 36, no. 15_suppl (Abstract ASCO 2018)

Spring 2018:

Following about two years of consultancy services for the Swiss bioetch start-up company Inthera Bioscience AG near Zürich, I took on their offer as Chief Development Officer starting in March 2018.

Sommer 2017:

Besides my activities as a consultant to the life science community, I have recently also discovered my interest in writing. Based on this I have now been able to publish my first book under my author´s name Bernard H. Bristling (www.bristling.de). It comprises a thrilling story situated in the modern biopharmaceutical research arena.

The book is available as ebook and as printed version at Amazon, written in german language and is called:

"Der geheime Histon-Code"

August 2016:

The publication mentioned below is now also available as printed version.

J Hepatol. 2016 Aug;65(2):280-8. doi: 10.1016/j.jhep.2016.02.043.

March 2016:

The clinical work on the use of the epigenetic drug resminostat in patients with liver cancer (HCC) has been published in the Journal of Hepatology.

Bitzer M, Horger M, Giannini EG, Ganten TM, Wörns MA, Siveke JT, Dollinger MM, Gerken G, Scheulen ME, Wege H, Zagonel V, Cillo U, Trevisani F, Santoro A, Montesarchio V, Malek NP, Holzapfel J, Herz T, Ammendola AS, Pegoraro S, Hauns B, Mais A, Lauer UM, Henning SW, Hentsch B (2016): Resminostat in combination with sorafenib as second-line therapy of advanced hepatocellular carcinoma - The SHELTER Study. J Hepatol. 2016 Mar 4. pii: S0168-8278(16)30009-5. doi: 10.1016/j.jhep.2016.02.043.
 

Spring 2014:

After spending more than 17 years in the biopharmaceutical industry, and thereof more than 12 years as Executive Board Member (CEO / CDO) of public and private biotech companies, I decided to provide my expertise in cancer research and cancer drug development also to a broader audience, i.e., those of you who set out to translate your research into new and improved cancer medications.